S&P 500   4,389.73 (-0.46%)
DOW   34,469.21 (+0.30%)
QQQ   350.05 (-0.92%)
AAPL   161.25 (-0.23%)
MSFT   293.50 (-0.97%)
FB   303.72 (-1.62%)
GOOGL   2,569.99 (-1.76%)
AMZN   2,808.77 (-2.84%)
TSLA   934.46 (+0.48%)
NVDA   225.70 (-3.43%)
BABA   120.04 (-0.27%)
NIO   24.13 (-2.98%)
AMD   112.55 (-3.42%)
CGC   7.43 (+0.41%)
MU   81.80 (-1.39%)
GE   91.26 (-5.83%)
T   26.48 (+0.53%)
F   20.11 (-1.37%)
DIS   136.73 (-0.53%)
AMC   16.03 (-3.67%)
PFE   52.74 (+2.33%)
ACB   4.24 (-1.85%)
BA   204.09 (-0.05%)
S&P 500   4,389.73 (-0.46%)
DOW   34,469.21 (+0.30%)
QQQ   350.05 (-0.92%)
AAPL   161.25 (-0.23%)
MSFT   293.50 (-0.97%)
FB   303.72 (-1.62%)
GOOGL   2,569.99 (-1.76%)
AMZN   2,808.77 (-2.84%)
TSLA   934.46 (+0.48%)
NVDA   225.70 (-3.43%)
BABA   120.04 (-0.27%)
NIO   24.13 (-2.98%)
AMD   112.55 (-3.42%)
CGC   7.43 (+0.41%)
MU   81.80 (-1.39%)
GE   91.26 (-5.83%)
T   26.48 (+0.53%)
F   20.11 (-1.37%)
DIS   136.73 (-0.53%)
AMC   16.03 (-3.67%)
PFE   52.74 (+2.33%)
ACB   4.24 (-1.85%)
BA   204.09 (-0.05%)
S&P 500   4,389.73 (-0.46%)
DOW   34,469.21 (+0.30%)
QQQ   350.05 (-0.92%)
AAPL   161.25 (-0.23%)
MSFT   293.50 (-0.97%)
FB   303.72 (-1.62%)
GOOGL   2,569.99 (-1.76%)
AMZN   2,808.77 (-2.84%)
TSLA   934.46 (+0.48%)
NVDA   225.70 (-3.43%)
BABA   120.04 (-0.27%)
NIO   24.13 (-2.98%)
AMD   112.55 (-3.42%)
CGC   7.43 (+0.41%)
MU   81.80 (-1.39%)
GE   91.26 (-5.83%)
T   26.48 (+0.53%)
F   20.11 (-1.37%)
DIS   136.73 (-0.53%)
AMC   16.03 (-3.67%)
PFE   52.74 (+2.33%)
ACB   4.24 (-1.85%)
BA   204.09 (-0.05%)
S&P 500   4,389.73 (-0.46%)
DOW   34,469.21 (+0.30%)
QQQ   350.05 (-0.92%)
AAPL   161.25 (-0.23%)
MSFT   293.50 (-0.97%)
FB   303.72 (-1.62%)
GOOGL   2,569.99 (-1.76%)
AMZN   2,808.77 (-2.84%)
TSLA   934.46 (+0.48%)
NVDA   225.70 (-3.43%)
BABA   120.04 (-0.27%)
NIO   24.13 (-2.98%)
AMD   112.55 (-3.42%)
CGC   7.43 (+0.41%)
MU   81.80 (-1.39%)
GE   91.26 (-5.83%)
T   26.48 (+0.53%)
F   20.11 (-1.37%)
DIS   136.73 (-0.53%)
AMC   16.03 (-3.67%)
PFE   52.74 (+2.33%)
ACB   4.24 (-1.85%)
BA   204.09 (-0.05%)
NASDAQ:PRAX

Praxis Precision Medicines Stock Forecast, Price & News

$14.80
+0.17 (+1.16%)
(As of 01/25/2022 03:07 PM ET)
Add
Compare
Today's Range
$13.38
$14.85
50-Day Range
$14.46
$20.61
52-Week Range
$12.71
$58.30
Volume
6,133 shs
Average Volume
192,105 shs
Market Capitalization
$663.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.42
30 days | 90 days | 365 days | Advanced Chart
Receive PRAX News and Ratings via Email

Sign-up to receive the latest news and ratings for Praxis Precision Medicines and its competitors with MarketBeat's FREE daily newsletter.


Praxis Precision Medicines logo

About Praxis Precision Medicines

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Cambridge, Massachusetts.

Headlines

Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 7.1%
January 25, 2022 |  americanbankingnews.com
Praxis Precision Medicines (NASDAQ:PRAX) Trading Up 3.5%
January 21, 2022 |  americanbankingnews.com
Praxis Precision Medicines (NASDAQ:PRAX) Shares Down 11.5%
January 18, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PRAX
Fax
N/A
Employees
2,020
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$7.51 per share

Profitability

Net Income
$-61.82 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
40,909,000
Market Cap
$663.87 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/03/2021
Today
1/25/2022
Next Earnings (Estimated)
3/16/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

592nd out of 1,415 stocks

Pharmaceutical Preparations Industry

283rd out of 683 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -












Praxis Precision Medicines (NASDAQ:PRAX) Frequently Asked Questions

Is Praxis Precision Medicines a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Praxis Precision Medicines in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Praxis Precision Medicines stock.
View analyst ratings for Praxis Precision Medicines
or view top-rated stocks.

Are investors shorting Praxis Precision Medicines?

Praxis Precision Medicines saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 1,820,000 shares, an increase of 21.3% from the December 15th total of 1,500,000 shares. Based on an average daily trading volume, of 247,600 shares, the days-to-cover ratio is presently 7.4 days. Currently, 4.9% of the shares of the company are short sold.
View Praxis Precision Medicines' Short Interest
.

When is Praxis Precision Medicines' next earnings date?

Praxis Precision Medicines is scheduled to release its next quarterly earnings announcement on Wednesday, March 16th 2022.
View our earnings forecast for Praxis Precision Medicines
.

How were Praxis Precision Medicines' earnings last quarter?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) released its earnings results on Wednesday, November, 3rd. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.93) by $0.07.
View Praxis Precision Medicines' earnings history
.

What price target have analysts set for PRAX?

4 analysts have issued 1 year target prices for Praxis Precision Medicines' shares. Their forecasts range from $28.00 to $48.00. On average, they anticipate Praxis Precision Medicines' stock price to reach $40.33 in the next twelve months. This suggests a possible upside of 172.5% from the stock's current price.
View analysts' price targets for Praxis Precision Medicines
or view top-rated stocks among Wall Street analysts.

Who are Praxis Precision Medicines' key executives?

Praxis Precision Medicines' management team includes the following people:
  • Mr. Marcio Souza, Pres, CEO & Director (Age 42, Pay $1.44M) (LinkedIn Profile)
  • Dr. Bernard Ravina, Chief Medical Officer (Age 54, Pay $799.81k)
  • Ms. Nicole Sweeny, Chief Commercial Officer (Age 46, Pay $310.9k)
  • Dr. David B. Goldstein Ph.D., Co-Founder
  • Dr. Steven Petrou, Co-Founder & Chief Scientific Officer
  • Mr. Timothy Edwin Kelly, CFO & Treasurer (Age 48)
  • Lauren Mastrocola, VP of Fin. & Principal Accounting Officer
  • Mr. Alex Nemiroff J.D., Gen. Counsel & Sec. (Age 42)
  • Ms. Kelly McCue, Chief People Officer
  • Mr. Karl Hansen, Sr. VP of CMC

When did Praxis Precision Medicines IPO?

(PRAX) raised $126 million in an IPO on Friday, October 16th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow acted as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

What is Praxis Precision Medicines' stock symbol?

Praxis Precision Medicines trades on the NASDAQ under the ticker symbol "PRAX."

How do I buy shares of Praxis Precision Medicines?

Shares of PRAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Praxis Precision Medicines' stock price today?

One share of PRAX stock can currently be purchased for approximately $14.80.

How much money does Praxis Precision Medicines make?

Praxis Precision Medicines has a market capitalization of $663.87 million. The company earns $-61.82 million in net income (profit) each year or ($3.46) on an earnings per share basis.

How many employees does Praxis Precision Medicines have?

Praxis Precision Medicines employs 2,020 workers across the globe.

What is Praxis Precision Medicines' official website?

The official website for Praxis Precision Medicines is www.praxismedicines.com.

Where are Praxis Precision Medicines' headquarters?

Praxis Precision Medicines is headquartered at 101 MAIN STREET #1210, CAMBRIDGE MA, 02142.

How can I contact Praxis Precision Medicines?

Praxis Precision Medicines' mailing address is 101 MAIN STREET #1210, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-300-8460 or via email at [email protected].


This page was last updated on 1/25/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.